ERN ReCONNET

ERN ReCONNET is the European Reference Network on Connective Tissue and Musculoskeletal Diseases. The main aim is to improve the management of rare connective tissue and musculo-skeletal diseases (rCTDs) across the EU. The main objectives of ERN ReCONNET are: - Realisation of the potential of European cooperation among rCTDs stakeholders, by providing a stable and fully functioning European infrastructure on rCTDs - Provision of highly-specialised care for rCTDs patients and promotion of improvements in the cost-effective delivery of diagnosis, management and monitoring of rCTDs patients - Pooling, advancing and exchanging of knowledge and information on rCTDs by providing training and education for rCTDs stakeholders and by facilitating the mobility of expertise - Stimulating and encouraging collaborative patient-centered research in rCTDs - Promoting the empowerment and the involvement of rCTDs patients in the rCTDs community. ERN ReCONNET currently covers the following rCTDs: - Antiphospholipid syndrome (APS) - Ehlers-Danlos syndromes (EDS) - Idiopathic inflammatory myopathies (IIM) - IgG4-related diseases (IgG4) - Mixed connective tissue diseases (MCTD) - Relapsing polychondritis (RP) - Sjögren’s syndrome (SS) - Systemic lupus erythematosus (SLE) - Systemic sclerosis (SSc) - Undifferentiated connective tissue diseases (UCTD) The ERN ReCONNET is a multi-stakeholder infrastructure which serves as a meeting point of needs, feedbacks and expertise for HCPs, patients, families and for other stakeholders involved in rCTDs. Currently, it involves 64 Healthcare Providers: 55 Full Members and 9 Affiliated Partners (APs) over 23 European countries: Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovenia, Spain, Sweden, and The Netherlands. ERN ReCONNET established active partnerships with patients’ representatives (ePAG Advocates).